@article{Liang2026, 
author = {Zishan Liang and Xian‐Yue Zeng and Jia‐Wei Lv and Guan‐Qun Zhou and Ying Sun and Li Lin},
title = {Advances in the Research of Nasopharyngeal Carcinoma: A Perspective},
year = {2026},
journal = {Cancer Innovation},
volume = {5},
number = {4},
pages = {e70074},
keywords = {antibody–drug conjugate, immunotherapy, nasopharyngeal carcinoma, precision radiotherapy},
url = {https://www.sciopen.com/article/10.1002/cai2.70074},
doi = {10.1002/cai2.70074},
abstract = {The year 2025 marked significant advances in precision medicine for nasopharyngeal carcinoma (NPC). This review summarizes recent advances in treatment strategies aimed at addressing longstanding challenges in NPC management, including treatment‐related toxicity, therapeutic resistance, and the limited precision of risk stratification. For locoregionally advanced NPC, a novel efficacy‐enhancing and toxicity‐minimizing strategy has emerged: toxicity minimizing involves replacing toxic concurrent cisplatin chemotherapy with PD‐1 blockade, achieving superior safety while maintaining non‐inferior 3‐year failure‐free survival; meanwhile efficacy‐enhancing employs adjuvant immunotherapy to improve survival specifically in high‐risk patients, supporting the transition toward risk‐adapted strategies. In radiotherapy, international consensus guidelines recommend reducing target volumes and sparing normal tissues to minimize side effects. For recurrent or metastatic NPC, antibody–drug conjugates(ADCs) and novel immunotherapeutic combinations show promise in overcoming treatment resistance and expanding therapeutic options. Furthermore, advances in artificial intelligence and deeper understanding of resistance mechanisms are accelerating clinical innovation. Collectively, these advances underscore the ongoing shift toward reduced toxicity, improved efficacy, and greater precision in the management of NPC.}
}